SecProbe.io

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                          August 26, 2025

Stephen Hurly
Chief Executive Officer and President
LAVA Therapeutics N.V.
Yalelaan 62
3584 CM Utrecht, The Netherlands

       Re: LAVA Therapeutics N.V.
           Schedule 14D-9 Filed August 15, 2025
           File No. 005-92425
Dear Stephen Hurly:

       We have reviewed your filing and have the following comments.

        Please respond to these comments by providing the requested information
or advise us
as soon as possible when you will respond. If you do not believe our comments
apply to your
facts and circumstances, please tell us why in your response.

        After reviewing your response to these comments, we may have additional
comments.
All defined terms used herein have the same meaning as in your Schedule 14D-9,
unless
otherwise indicated.

Schedule 14D-9 Filed August 15, 2025
Reasons for the Recommendation of the LAVA Board, page 24

1.     On page 25, we note that the LAVA Board considered the "assets,
liabilities and
       financial condition of the Company on a standalone basis" in reaching
its
       recommendation to shareholders. However, on page 32, we note that "LAVA
advised
       Leerink Partners that it did not have a standalone business plan and its
plan in the
       absence of a sale or merger of the company was to pursue a dissolution
of LAVA."
       Therefore, please revise this section to further explain the LAVA
Board's evaluation
       of the Company's prospects on a standalone basis.
2.     See our last comment above. We note that upfront consideration
represented by the
       Cash Amount ($1.16 - $1.24 per Share) represents a discount to the
market price at or
       around the time that the Offer commenced (e.g., the closing market price
was $1.54
       per Share on August 14, 2025). Please revise to discuss what
consideration the LAVA
       Board gave to the market price per Share in determining that the
Purchase Agreement
       and the Transactions are in the best interest of LAVA.
 August 26, 2025
Page 2

Opinion of Leerink Partners LLC, page 29

3.     See comment 1 above. On page 32, we note that Leerink Partners concluded
that
          traditional valuation methodologies typically used for purposes of
valuing a business
       as a going concern were not applicable to LAVA    given that LAVA did
not have a
       standalone business plan. However, on page 30, we note that in addition
to reviewing
       the Dissolution Analysis,    Leerink Partners also conducted such other
financial
       studies and analyses . . . as it deemed appropriate    in rendering its
opinion. Please
       identify these    other financial studies and analyses    and explain
how they were
       considered by Leerink Partners.
        We remind you that the filing persons are responsible for the accuracy
and adequacy
of their disclosures, notwithstanding any review, comments, action or absence
of action by
the staff.

       Please direct any questions to Shane Callaghan at 202-551-6977.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Mergers &
Acquisitions
</TEXT>
</DOCUMENT>